Secondly, the most compelling mechanistic explanation of FGF23’s involvement in CKD-related hypertrophy is based on studies where FGFR4 but not FGF23 were selectively targeted by monoclonal antibodies25. This evidence concerns the gene FGF23 and chronic kidney disease.